Search Results

Results of Quality-of-Life Assessment Published From the PARTNER S3i Trial

June 18, 2018—Suzanne J. Baron, MD, et al published findings from a study that sought to evaluate whether transcatheter aortic valve replacement (TAVR) with the Sapien 3 transcatheter heart valve (S3-TAVR; Edwards Lifesciences) results in improved quality of life (QOL) compared with previous-generation TAVR devices or surgical aortic valve replacement (SAVR). The study is available online in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

COAPT Economic Analysis Demonstrates Cost-Effectiveness of TMVR With MitraClip

September 29, 2019—The Cardiovascular Research Foundation (CRF) announced that results from a new economic analysis of the COAPT trial data were presented by Suzanne J. Baron, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California. The results were published simultaneously by Dr. Baron et al online in Circulation.

PARTNER 3 Quality-of-Life Substudy Shows Sustained Health Status for TAVR at 1 Year

September 29, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the PARTNER 3 Quality-of-Life Substudy were presented by Suzanne J. Baron, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California. Dr. Baron et al published the findings online in Journal of the American College of Cardiology.

Evaluation of PARTNER II Compares Cost-Effectiveness of TAVR and SAVR

February 19, 2019—Findings from an evaluation of the cost-effectiveness of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe aortic stenosis (AS) in the PARTNER II trial were published by Suzanne J. Baron, MD, et al in Circulation (2018;139:877–888).

ShortCUT Compares Cutting Balloon Angioplasty Versus IVL Before Stenting in Calcified CAD

October 26, 2025—Results from the ShortCUT randomized controlled trial showed that cutting balloon (CB) angioplasty was noninferior to intravascular lithotripsy (IVL) in a direct comparison of the safety and efficacy of the two treatment strategies before drug-eluting stent (DES) implantation for the treatment of calcified coronary artery disease.

EXCEL Substudy Compares Quality-of-Life Outcomes in Left Main Disease Treated With PCI Versus CABG

October 30, 2017—Results from the EXCEL trial comparing the quality of life (QOL) of patients with left main coronary artery disease (LMCAD) receiving percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) found significant and similar QOL improvement at 3 years, although a greater benefit was observed with PCI at 1 month.

Edwards' Sapien 3 TAVR System Approved in Europe for Low-Risk Patients

November 6, 2019—Edwards Lifesciences announced that it has received CE Mark approval to expand use of the Sapien 3 transcatheter heart valve for the treatment of patients with aortic stenosis who are at low risk for open heart surgery.

Edwards Highlights New Data on Lifetime Management of Aortic Stenosis

March 6, 2023—Edwards Lifesciences highlighted new data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) patients, along with data examining 10-year transcatheter aortic valve replacement (TAVR) reintervention rates using real-world Medicare data.

Edwards Highlights Studies on the Impact of the Undertreatment of Aortic Stenosis Published in 2022

December 13, 2022—Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis.